RAPT: RAPT Therapeutics, Inc. Growth-Adjusted Market Cap to Net Income
Anticipation of FDA approval and the relaunch of immune molecule trials create growth potential, which this growth-adjusted P/E chart on GURU.Markets visualizes via 0.00, indicating the current level. RAPT Therapeutics, Inc. (RAPT) develops oral treatments for cancer and inflammation, aiming to block specific receptors. Partnership grants and external investments provide the startup's funding.
Metric breakdowns and analytics for RAPT Therapeutics (RAPT)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
RAPT - Company Net Income|Forward Earnings RAPT Therapeutics, Inc.|RAPT - Price to Earnings Ratio|Market Cap to Future Earnings Ratio rapt.com|RAPT - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation RAPT|RAPT - Operating profit before deduction of amortization|Earnings per share for the last four quarters RAPT Therapeutics|RAPT - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months rapt.com|RAPT - Earnings growth in current year|Expected net earnings per share growth next year RAPT Therapeutics, Inc.
General company analysis:RAPT - rapt.com
The metric is calculated as the ratio of the P/E multiple to the earnings growth rate, allowing for an assessment of the cost of each unit of future business growth. By analyzing the PEG ratio, an investor can identify the fundamental undervaluation of an asset, which is critically important for RAPT Therapeutics, Inc. (RAPT) and its model of developing targeted molecules through grants and partnerships in the therapy of immune disorders.
Competitors of RAPT Therapeutics, Inc.
ARGX (argenx N.V.) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (BioNTech Group)|Growth-Adjusted Market Cap to Net Income Abivax (ABVX)|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|Immunovant (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals, Ltd.|Price/Earnings to Growth Multiple GRFS|PEG Multiple Adaptive Biotechnologies Inc.|Price/Earnings to Growth Ratio Celldex Therapeutics (CLDX)|auriniapharma.com - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - Price to Earnings Adjusted for Growth Rate|DNTH - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio PHVS (Pharvaris Pharma)|ABCL: PEG Multiple|tourmalinebio.com (TRML) - PEG Multiple|Price/Earnings to Growth Ratio Precigen|Pharming Group NV - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple NKTR (Nektar)|Company Value to Earnings Growth Ratio UPB|Zenas Biopharma Inc - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio IMNM|GOSS: Price/Earnings to Growth Multiple|KalVista Pharma - Company Value to Earnings Growth Ratio|SEPN: PEG Multiple|Pieris Corp - Growth-Adjusted Payback Ratio|SVRA (Savara Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate rigel.com RIGL|Price/Earnings to Growth Ratio AnaptysBio (ANAB)|ATXS (Astria Therapeutics Inc) - Growth-Adjusted Payback Ratio|PEG Multiple ENGN (enGene Bio)|PEG Multiple Aerovate Therapeutics, Inc. JBIO|ACRS - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio KYTX|TLSA: PEG Multiple|Price to Earnings Adjusted for Growth Rate Cabaletta Bio Inc. (CABA)|Price/Earnings to Growth Multiple VTYX|PEG Multiple Theratechnologies, Inc|Price/Earnings to Growth Multiple AVTX (Avalo Therapeutics, Inc)|Company Value to Earnings Growth Ratio ELDN|PEG Multiple AGEN (Agenus Inc.)|Growth-Adjusted Market Cap to Net Income Climb Bio Inc. (CLYM)|Zura Bio Limited - PEG Multiple|aTyr Pharmaceuticals (ATYR) - Price/Earnings to Growth Multiple|adagene.com (ADAG) - Price/Earnings to Growth Ratio|IMA - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple STTK|EQ: Growth-Adjusted Payback Ratio|PEG Multiple CNTB|Growth-Adjusted Market Cap to Net Income immunic-therapeutics.com|Price/Earnings to Growth Ratio Atara Bio ATRA|IFRX: Growth-Adjusted P/E Ratio|X4 Pharmaceuticals, Inc. - PEG Multiple|Adicet Bio (ACET) - Price/Earnings to Growth Multiple|CELU (celularity.com) - Price/Earnings to Growth Multiple|INMB - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Barinthus Biotherapeutics|KZR: Growth-Adjusted Payback Ratio|PEG Multiple SABS|PEG Multiple Akari Therapeutics PLC (AKTX)|Price/Earnings to Growth Ratio Enlivex Therapeutics Ltd. ENLV|QTTB (Q32 Bio Inc) - Market Cap to Earnings and Growth Ratio|GOVX: Price/Earnings to Growth Multiple|edesabiotech.com - Company Value to Earnings Growth Ratio|iBio (IBIO) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio CARM (Carisma Therapeutics Inc.)|XTLB (XTL Biopharmaceuticals, Ltd.) - PEG Multiple|BOLT: Growth-Adjusted Payback Ratio|PEG Multiple HCWB|PEG Multiple aptevotherapeutics.com (APVO)|Price/Earnings to Growth Ratio AIM ImmunoTech AIM|Growth-Adjusted Payback Ratio ADTX|GRI - Price/Earnings to Growth Ratio|XORTX Corp (XRTX) - Price/Earnings to Growth Multiple|HIND: PEG Multiple|revbiosciences.com (REVB) - PEG Multiple|Price/Earnings to Growth Multiple INDP|SCNI: Growth-Adjusted Payback Ratio|PEG Multiple CALI|Growth-Adjusted Market Cap to Net Income affimed.com|Price/Earnings to Growth Ratio Allakos ALLK|HOOK - Price/Earnings to Growth Multiple|IGMS - Price/Earnings to Growth Ratio|iTeos Therapeutics Inc (ITOS) - Price/Earnings to Growth Multiple|OCEA (Ocean Bio) - Price/Earnings to Growth Multiple|TC BioPharm Ltd (TCBP) - PEG Multiple|Price/Earnings to Growth Ratio Third Harmonic Bio
